title: Profiling Differential Responses to Pan-HER Inhibition.
abstract: Findings from the phase II SUMMIT basket trial indicate that among patients with solid cancers harboringHER2/3mutations, responses to the investigational pan-HER inhibitor neratinib vary by specific alteration and tumor type. Neratinib showed promising single-agent activity in breast, biliary tract, and cervical cancers, but was ineffective against bladder and colorectal cancers; among a small subset of patients withHER3mutations, no responses were seen.